市場調查報告書

唐氏症:至2030年的市場分析,流行病學,預測

Down Syndrome- Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 968101
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
唐氏症:至2030年的市場分析,流行病學,預測 Down Syndrome- Market Insight, Epidemiology and Market Forecast -2030
出版日期: 2020年10月30日內容資訊: 英文 162 Pages
簡介

本報告提供美國,德國,法國,義大利,西班牙,英國,日本的主要7個國家的唐氏症的流行病學市場調查,疾病概要,流行病學與患者數,目前治療方法,未滿足需求,新的治療方法,各國市場分析,促進市場成長的要素及阻礙因素,案例研究等資訊。

目錄

第1章 主要調查結果

第2章 市場概要

第3章 摘要整理

第4章 組織

第5章 疾病概要

  • 簡介
  • 症狀
  • 種類
  • 危險因素
  • 遺傳的基礎
    • 基因表現變異
  • 病因
    • 表現型的偏差
    • 代謝的不平衡
  • 臨床症狀
  • 診斷

第6章 流行病學和患者數

  • 主要調查結果
  • 的診斷患者數主要7個國家

第7章 主要7個國家的流行病學

  • 前提和根據
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 目前治療方法

  • 管理的指南
  • American College of Obstetricians and Gynecologists
  • Health Care Guidelines for People with Down syndrome: European Down syndrome Association

第9章 未滿足需求

第10章 新治療方法

  • 主要的競爭產品
  • ACI-24:AC Immune
    • 概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • ANVS-401:Annovis Bio
    • 概要
    • 其他開發活動
  • ALZ-801:Alzheon
    • 其他開發活動
  • ELND005:OPKO Health, Inc.
    • 其他開發活動
  • AEF0217:Aelis Farma

第11章 主要7個國家的市場分析

  • 主要調查結果
  • 市場規模
  • 市場預測
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第12章 促進市場成長的要素

第13章 市場障礙

第14章 市場進入與償付

第15章 SWOT分析

第16章 案例研究

第17章 主要專家的見解

第18章 附錄

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

目錄
Product Code: DIMI0375

DelveInsight's "Down Syndrome (DS) - Market Insights, Epidemiology, and Market Forecast - 2030" report delivers an in-depth understanding of the historical and forecasted epidemiology and the market trends of Down syndrome (DS) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Down syndrome (DS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Down syndrome market Size from 2017 to 2030, segmented by seven major markets. The report also covers current Down syndrome (DS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Down syndrome (DS) Disease Understanding and Treatment Algorithm

Down syndrome (DS) Overview

Down syndrome (DS) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor. It is a chromosomal condition associated with intellectual disability, a characteristic facial appearance, and weak muscle tone (hypotonia) in infancy. All affected individuals experience cognitive delays, but the intellectual disability is usually mild to moderate.

It is a genetic disorder, which is due to the presence of 47 chromosomes instead of 46, with an extra copy of chromosome 21. The extra copy of chromosome 21, which may either be full or partial, depending on the variant, causes the abnormality and associated structural and functional anomalies of the bodily systems. There are three types of Down syndrome: trisomy 21 (nondisjunction), translocation, and mosaicism. Trisomy 21, the most common type of Down syndrome, occurs when there are three, rather than two, number 21 chromosomes present in every cell of the body.

Regardless of the type of Down syndrome a person may have, all people with DS have an extra, critical portion of chromosome 21 present in all or some of their cells. This additional genetic material alters the course of development and causes the characteristics associated with the condition.

The cause of the extra full or partial chromosome is still unknown. Maternal age is the only factor that has been linked to an increased chance of having a baby with Down syndrome resulting from nondisjunction or mosaicism. However, due to higher birth rates in younger women, 80% of children with Down syndrome are born to women under 35.

It is the most commonly diagnosed chromosomal abnormality in live-born infants and the most recognized congenital aneuploidy (presence of an erroneous number of chromosomes, e.g., 45 or 47) associated with delayed physical and mental development.

Down syndrome (DS) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Down syndrome (DS) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Down syndrome (DS) market report gives a thorough understanding of Down syndrome symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Down syndrome symptoms of treatment algorithms and treatment guidelines for Down syndrome symptoms in the US, Europe, and Japan.

Down syndrome (DS) Epidemiology

The Down syndrome symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Down syndrome (DS) epidemiology segmented as the total diagnosed prevalent cases of Down syndrome, type-specific diagnosed prevalent population of Down syndrome, gender-specific diagnosed prevalent population of Down syndrome, age-specific diagnosed prevalent population of Down syndrome, and diagnosed prevalent population of down syndrome by clinical manifestation. The report includes the prevalent scenario of Down syndrome symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Down Syndrome (DS) Epidemiology

The epidemiology segment also provides the Down syndrome (DS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent population of Down syndrome (DS) in 7MM countries was estimated to be 699,750 cases in 2017.

Down syndrome (DS) Drug Chapters

The drug chapter segment of the Down syndrome (DS) report encloses the detailed analysis of Down syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Down syndrome (DS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

Down syndrome (DS) Emerging Drugs

ANVS-401 (Annovis Bio)

Annovis Bio is developing ANVS-401 as a combination therapy approach to inhibit the translation of multiple neurotoxic proteins such as APP/AB, tau/phospho-tau, and α-synuclein. The ANVS-401 may improve the axonal transport, increase synaptic transmission, prevent inflammation, and restore cascade events by reducing APP, tau, and Alpha-synuclein levels and preserving the health of nerve cells. The company is planning to obtain human data for AD in Down syndrome than in the regular AD population. Henceforth, it plans to conduct Phase III pivotal study in AD-DS rather than in AD.

Products detail in the report…

Down syndrome (DS) Market Outlook

The Down syndrome (DS) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Down syndrome (DS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Down syndrome (DS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Down syndrome (DS) market in 7MM is expected to change in the study period 2017-2030.

The current market of Down syndrome is dominated by the use of supportive therapies depending on the manifestations such as anti-anxiety medications, anticonvulsants, antidepressants, anti-hypertension medications, antipsychotic medications, antispasmodics, cholesterol-lowering medications, cholinesterase inhibitors, GERD-related medications (e.g., proton pump inhibitors), hormones (other than thyroid-related hormones and others.

Key Findings

This section includes a glimpse of the Down syndrome (DS) market in 7MM. The market size of Down syndrome in the seven major markets was found to be USD 662.9 million in 2017.

The United States Market Outlook

This section provides the total Down syndrome (DS) market size and market size by therapies in the United States.

The United States accounts for the highest market size of Down syndrome in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

For tonic-clonic seizures or infantile spasms, anticonvulsants are generally provided. In the case of psychiatric disorders, pharmacologic agents, psychotherapy, or behavioral therapy are recommended. For skin disorders, weight reduction, proper hygiene, frequent baths, antibiotic ointment, or systemic antibiotic therapy are recommended. Furthermore, for dental caries and periodontal disease, appropriate dental hygiene, fluoride treatments, good dietary habits, and restorative care are generally considered.

EU-5 Countries: Market Outlook

The total Down syndrome (DS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

In Europe, the prevalence of Down syndrome has increased over time, and scientists attribute this to the steady increase in the average maternal age, as the condition is known to be more frequent in children born to older mothers. Scientists also point to regional differences in pregnancy outcomes and prenatal diagnoses across Europe.

While some physical deficits in DS may be corrected with surgery, medications are often used to manage various comorbid health conditions in individuals with DS. Rivastigmine, galantamine, memantine, and donepezil have been used to treat Down syndrome-associated dementia (DSAD). Other studies did not show significant improvement in subjects with DSAD who were treated with donepezil. Patients with DS can have high utilization rates of antidepressant and antipsychotic medications.

Japan Market Outlook

The total Down syndrome (DS) market size and market size by therapies in Japan are also mentioned.

Down syndrome (DS) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Down syndrome (DS) market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Down Syndrome (DS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Down syndrome (DS) key players involved in developing targeted therapeutics.

Some of the major players and their rug candidates expected to get launched during the forecast period (2020-2030) include Annovis Bio (ANVS-401), AC Immune (ACI-24), Alzheon (ALZ-801), Balance Therapeutics (BTD-001), Aelis Farma (AEF0217), and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, mergers and acquisitions, licensing, and patent details for Down syndrome (DS) emerging therapies.

Reimbursement Scenario in Down syndrome (DS)

Many children with DS are included as secondary subscribers under their parents' employer-subsidized healthcare plans. In this case, those families who have higher deductibles might end up having more out-of-pocket expenses simply because children with DS typically have more outpatient appointments than neurotypically developing peers have. Children and adolescents with non-mosaic DS are also automatically eligible for Medicaid as either a primary or secondary healthcare insurance; however, co-pays can vary based on parental income and differing state regulations. For instance, a single-parent, low-income household might have all of the out-of-pocket healthcare expenditures for a child with DS covered by Medicaid; whereas, a middle-income household might have a monthly co-pay for the same Medicaid coverage.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Down syndrome (DS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Down syndrome (DS) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Down syndrome (DS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Down syndrome (DS), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Down syndrome (DS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Down syndrome (DS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Down syndrome (DS) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Down syndrome (DS) market

Report Highlights:

  • In the coming years, the Down syndrome (DS) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Down syndrome (DS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Down syndrome. The launch of emerging therapies will significantly impact the Down syndrome (DS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Down syndrome.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Down syndrome (DS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Down syndrome (DS) Pipeline Analysis
  • Down syndrome (DS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Down syndrome (DS) Report Key Strengths

  • 11-years Forecast
  • 7MM Coverage
  • Down syndrome (DS) Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Down syndrome (DS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Down syndrome (DS) Market share (%) distribution in 2017, and how would it look like in 2030?
  • What would be the Down syndrome (DS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings of the market across 7MM, and which country will have the largest Down syndrome (DS) market Size during the forecast period (2017-2030)?
  • At what CAGR, the Down syndrome (DS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Down syndrome (DS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Down syndrome (DS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Down syndrome (DS)?
  • What is the historical Down syndrome (DS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Down syndrome (DS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population with Down syndrome (DS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Down syndrome (DS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Down syndrome (DS)?
  • What are the current treatment guidelines for the treatment of Down syndrome (DS) in the USA, Europe, and Japan?
  • What are the Down syndrome (DS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Down syndrome (DS)?
  • How many therapies are developed by each company for the treatment of Down syndrome (DS)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Down syndrome (DS)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Down syndrome (DS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Down syndrome (DS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Down syndrome (DS)?
  • What are the global historical and forecasted market of Down syndrome (DS)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Down syndrome (DS) market
  • To understand the future market competition in the Down syndrome (DS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Down syndrome (DS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Down syndrome (DS) market
  • To understand the future market competition in the Down syndrome (DS) market

Table of Contents

1. Key Insights

2. Down syndrome: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Down syndrome in 2017
  • 2.2. Market Share (%) Distribution of Down syndrome in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Down syndrome

  • 5.1. Introduction
  • 5.2. Symptoms
  • 5.3. Types of Down syndrome
  • 5.4. Risk factors for Down syndrome
  • 5.5. Genetic Basis of Down syndrome
    • 5.5.1. Gene expression variation
  • 5.6. Etiopathogenesis
    • 5.6.1. Phenotypic Variability of Down syndrome
    • 5.6.2. Metabolic Imbalance in Down syndrome
  • 5.7. Clinical Conditions Associated with Down syndrome
  • 5.8. Diagnosis of Down syndrome

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Total Diagnosed Prevalent Population of Down syndrome in 7MM

7. 7 MM-Epidemiology of Down syndrome

  • 7.1. Assumptions and Rationale
  • 7.2. United States
  • 7.3. Total Diagnosed Prevalent Cases of Down syndrome in the US
  • 7.4. Gender-specific cases of Down syndrome in the US
  • 7.5. Type-specific cases of Down syndrome in the US
  • 7.6. Age-specific cases of Down syndrome in the US
  • 7.7. Diagnosed cases of Down syndrome by Clinical Manifestations in the US
  • 7.8. Germany
    • 7.8.1. Total Diagnosed Prevalent Cases of Down syndrome in Germany
    • 7.8.2. Gender-specific cases of Down syndrome in Germany
    • 7.8.3. Type-specific cases of Down syndrome in Germany
    • 7.8.4. Age-specific cases of Down syndrome in Germany
    • 7.8.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Germany
  • 7.9. France
    • 7.9.1. Total Diagnosed Prevalent Cases of Down syndrome in France
    • 7.9.2. Gender-specific cases of Down syndrome in France
    • 7.9.3. Type-specific cases of Down syndrome in France
    • 7.9.4. Age-specific cases of Down syndrome in France
    • 7.9.5. Diagnosed cases of Down syndrome by Clinical Manifestation in France
  • 7.10. Italy
    • 7.10.1. Total Diagnosed Prevalent Cases of Down syndrome in Italy
    • 7.10.2. Gender-specific cases of Down syndrome in Italy
    • 7.10.3. Type-specific cases of Down syndrome in Italy
    • 7.10.4. Age-specific cases of Down syndrome in Italy
    • 7.10.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Italy
  • 7.11. Spain
    • 7.11.1. Total Diagnosed Prevalent Cases of Down syndrome in Spain
    • 7.11.2. Gender-specific cases of Down syndrome in Spain
    • 7.11.3. Type-specific cases of Down syndrome in Spain
    • 7.11.4. Age-specific cases of Down syndrome in Spain
    • 7.11.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Spain
  • 7.12. The UK
    • 7.12.1. Total Diagnosed Prevalent Cases of Down syndrome in the UK
    • 7.12.2. Gender-specific cases of Down syndrome in the UK
    • 7.12.3. Type-specific cases of Down syndrome in the UK
    • 7.12.4. Age-specific cases of Down syndrome in the UK
    • 7.12.5. Diagnosed cases of Down syndrome by Clinical Manifestation in the UK
  • 7.13. Japan
    • 7.13.1. Total Diagnosed Prevalent Cases of Down syndrome in Japan
    • 7.13.2. Gender-specific cases of Down syndrome in Japan
    • 7.13.3. Type-specific cases of Down syndrome in Japan
    • 7.13.4. Age-specific cases of Down syndrome in Japan
    • 7.13.5. Diagnosed cases of Down syndrome by Clinical Manifestation in Japan

8. Current Treatment Practices

  • 8.1. Management Guidelines
  • 8.2. American College of Obstetricians and Gynecologists
  • 8.3. Health Care Guidelines for People with Down syndrome: European Down syndrome Association

9. Unmet needs

10. Emerging Therapies

  • 10.1. Key cross Analysis
  • 10.2. ACI-24: AC Immune
    • 10.2.1. Drug Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. ANVS-401: Annovis Bio
    • 10.3.1. Drug description
    • 10.3.2. Other Development Activities
    • 10.3.3. Safety and Efficacy
    • 10.3.4. Product Profile
  • 10.4. ALZ-801: Alzheon
    • 10.4.1. Drug Description
    • 10.4.2. Other Developmental Activity
    • 10.4.3. Safety and Efficacy
    • 10.4.4. Product Profile
  • 10.5. ELND005: OPKO Health, Inc.
    • 10.5.1. Drug Description
    • 10.5.2. Other developmental Activities
    • 10.5.3. Clinical Development
    • 10.5.4. Safety and Efficacy
    • 10.5.5. Product Profile
  • 10.6. AEF0217: Aelis Farma
    • 10.6.1. Drug Description
    • 10.6.2. Product Profile

11. Down syndrome: Seven Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Down syndrome in 7MM
  • 11.3. Market outlook
  • 11.4. United States: Market Size
    • 11.4.1. The total market size of Down syndrome in the United States
    • 11.4.2. Therapy Based Market Size of Down syndrome in the US
  • 11.5. Germany: Market Size
    • 11.5.1. The total market size of Down syndrome in Germany
    • 11.5.2. Therapy Based Market Size of Down syndrome in Germany
  • 11.6. France: Market Size
    • 11.6.1. The total market size of Down syndrome in France
    • 11.6.2. Therapy Based Market Size of Down syndrome in France
  • 11.7. Italy: Market Size
    • 11.7.1. The total market size of Down syndrome in Italy
    • 11.7.2. Therapy Based Market Size of Down syndrome in Italy
  • 11.8. Spain: Market Size
    • 11.8.1. The total market size of Down syndrome in Spain
    • 11.8.2. Therapy Based Market Size of Down syndrome in Spain
  • 11.9. The UK: Market Size
    • 11.9.1. The total market size of Down syndrome in the UK
    • 11.9.2. Therapy Based Market Size of Down syndrome in the UK
  • 11.10. Japan Market Size
    • 11.10.1. The total market size of Down syndrome in Japan
    • 11.10.2. Therapy Based Market Size of Down syndrome in Japan

12. Market Drivers

13. Market Barriers

14. Market Access and Reimbursement

15. SWOT Analysis

16. Case studies

  • 16.1. Neurodevelopmental Progress for Male Child with Down syndrome, Nystagmus, Myopia and Severe Digestive Issues with Pica
  • 16.2. Jeffery: A toddler with Down syndrome
  • 16.3. Alzheimer's disease in Down syndrome: A Neuropsychological Case Study

17. KOL views

18. Appendix

  • 18.1. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

  • Table 1: Candidate dosage-sensitive genes on chromosome 21causing DS phenotype
  • Table 2: Common techniques used for the diagnosis of Down's syndrome along with its advantages and disadvantages
  • Table 3: Total Prevalent Patient Population of Down syndrome in the 7MM (2017-2030)
  • Table 4: Total Diagnosed Prevalent Cases of Down syndrome in the US (2017-2030)
  • Table 5: Gender-specific cases of Down syndrome in the US (2017-2030)
  • Table 6: Type-specific cases of Down syndrome in the US (2017-2030)
  • Table 7: Age-specific cases of Down syndrome in the US (2017-2030)
  • Table 8: Diagnosed cases of Down syndrome by Clinical Manifestation in the US (2017-2030)
  • Table 9: Total Diagnosed Prevalent Cases of Down syndrome in Germany (2017-2030)
  • Table 10: Gender-specific cases of Down syndrome in Germany (2017-2030)
  • Table 11: Type-specific cases of Down syndrome in Germany (2017-2030)
  • Table 12: Age-specific cases of Down syndrome in Germany (2017-2030)
  • Table 13: Diagnosed cases of Down syndrome by Clinical Manifestation in Germany (2017-2030)
  • Table 14: Total Diagnosed Prevalent Cases of Down syndrome in France (2017-2030)
  • Table 15: Gender-specific cases of Down syndrome in France (2017-2030)
  • Table 16: Type-specific cases of Down syndrome in France (2017-2030)
  • Table 17: Age-specific cases of Down syndrome in France (2017-2030)
  • Table 18: Diagnosed cases of Down syndrome by Clinical Manifestation in France (2017-2030)
  • Table 19: Total Diagnosed Prevalent Cases of Down syndrome in Italy (2017-2030)
  • Table 20: Gender-specific cases of Down syndrome in Italy (2017-2030)
  • Table 21: Type-specific cases of Down syndrome in Italy (2017-2030)
  • Table 22: Age-specific cases of Down syndrome in Italy (2017-2030)
  • Table 23: Diagnosed cases of Down syndrome by Clinical Manifestation in Italy (2017-2030)
  • Table 24: Total Diagnosed Prevalent Cases of Down syndrome in Spain (2017-2030)
  • Table 25: Gender-specific cases of Down syndrome in Spain (2017-2030)
  • Table 26: Type-specific cases of Down syndrome in Spain (2017-2030)
  • Table 27: Age-specific cases of Down syndrome in Spain (2017-2030)
  • Table 28: Diagnosed cases of Down syndrome by Clinical Manifestation in Spain (2017-2030)
  • Table 29: Total Diagnosed Prevalent Cases of Down syndrome in the UK (2017-2030)
  • Table 30: Gender-specific cases of Down syndrome in the UK (2017-2030)
  • Table 31: Type-specific cases of Down syndrome in the UK (2017-2030)
  • Table 32: Age-specific cases of Down syndrome in the UK (2017-2030)
  • Table 33: Diagnosed cases of Down syndrome by Clinical Manifestation in the UK (2017-2030)
  • Table 34: Total Diagnosed Prevalent Cases of Down syndrome in Japan (2017-2030)
  • Table 35: Gender-specific cases of Down syndrome in Japan (2017-2030)
  • Table 36: Type-specific cases of Down syndrome in Japan (2017-2030)
  • Table 37: Age-specific cases of Down syndrome in Japan (2017-2030)
  • Table 38: Diagnosed cases of Down syndrome by Clinical Manifestation in Japan (2017-2030)
  • Table 39: Emerging Drugs Analysis, 2020
  • Table 40: Preclinical Drugs Analysis, 2020
  • Table 41: ACI-24 Clinical Trial Description, 2020
  • Table 42: ELND005 Clinical Trial Description, 2020
  • Table 43: 7 Major Market Size of Down syndrome in USD Million (2017-2030)
  • Table 44: The US Market Size of Down syndrome in USD Million (2017-2030)
  • Table 45: Therapy Based Market Size of Down syndrome in the US in USD Million (2017-2030)
  • Table 46: Germany Market Size of Down syndrome in USD Million (2017-2030)
  • Table 47: Therapy Based Market Size of Down syndrome in Germany in USD Million (2017-2030)
  • Table 48: France Market Size of Down syndrome in USD Million (2017-2030)
  • Table 49: Therapy Based Market Size of Down syndrome in France in USD Million (2017-2030)
  • Table 50: Italy Market Size of Down syndrome in USD Million (2017-2030)
  • Table 51: Therapy Based Market Size of Down syndrome in Italy in USD Million (2017-2030)
  • Table 52: Spain Market Size of Down syndrome in USD Million (2017-2030)
  • Table 53: Therapy Based Market Size of Down syndrome in Spain in USD Million (2017-2030)
  • Table 54: The UK Market Size of Down syndrome in USD Million (2017-2030)
  • Table 55: Therapy Based Market Size of Down syndrome in the UK in USD Million (2017-2030)
  • Table 56: Japan Market Size of Down syndrome in USD Million (2017-2030)
  • Table 57:Therapy Based Market Size of Down syndrome in Japan in USD Million (2017-2030)

List of Figures

  • Figure 1: Physical Symptoms
  • Figure 2: Developmental and Behavioral Symptoms
  • Figure 3: Types of Down syndrome
  • Figure 4: Comparison of balanced translocation and translocation DS Karyotype
  • Figure 5: Risk Factors for Down syndrome
  • Figure 6: Clinical conditions associated with Down syndrome
  • Figure 7: Karyotyping for diagnosis of Down syndrome
  • Figure 8: Total Prevalent Patient Population of Down syndrome in 7MM (2017-2030)
  • Figure 9: Total Diagnosed Prevalence of Down syndrome in the US (2017-2030)
  • Figure 10: Gender-specific cases of Down syndrome in the US (2017-2030)
  • Figure 11: Type-specific cases of Down syndrome in the US (2017-2030)
  • Figure 12: Age-specific cases of Down syndrome in the US (2017-2030)
  • Figure 13: Diagnosed cases of Down syndrome by Clinical Manifestation in the US (2017-2030)
  • Figure 14: Total Diagnosed Prevalence of Down syndrome in Germany (2017-2030)
  • Figure 15: Gender-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 16: Type-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 17: Age-specific cases of Down syndrome in Germany (2017-2030)
  • Figure 18: Diagnosed cases of Down syndrome by Clinical Manifestation in Germany (2017-2030)
  • Figure 19: Total Diagnosed Prevalence of Down syndrome in France (2017-2030)
  • Figure 20: Gender-specific cases of Down syndrome in France (2017-2030)
  • Figure 21: Type-specific cases of Down syndrome in France (2017-2030)
  • Figure 22: Age-specific cases of Down syndrome in France (2017-2030)
  • Figure 23: Diagnosed cases of Down syndrome by Clinical Manifestation in France (2017-2030)
  • Figure 24: Total Diagnosed Prevalence of Down syndrome in Italy (2017-2030)
  • Figure 25: Gender-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 26: Type-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 27: Age-specific cases of Down syndrome in Italy (2017-2030)
  • Figure 28: Diagnosed cases of Down syndrome by Clinical Manifestation in Italy (2017-2030)
  • Figure 29: Total Diagnosed Prevalence of Down syndrome in Spain (2017-2030)
  • Figure 30: Gender-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 31: Type-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 32: Age-specific cases of Down syndrome in Spain (2017-2030)
  • Figure 33: Diagnosed cases of Down syndrome by Clinical Manifestation in Spain (2017-2030)
  • Figure 34: Total Diagnosed Prevalence of Down syndrome in the UK (2017-2030)
  • Figure 35: Gender-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 36: Type-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 37: Age-specific cases of Down syndrome in the UK (2017-2030)
  • Figure 38: Diagnosed cases of Down syndrome by Clinical Manifestation in the UK (2017-2030)
  • Figure 39: Total Diagnosed Prevalence of Down syndrome in Japan (2017-2030)
  • Figure 40: Gender-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 41: Type-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 42: Age-specific cases of Down syndrome in Japan (2017-2030)
  • Figure 43: Diagnosed cases of Down syndrome by Clinical Manifestation in Japan (2017-2030)
  • Figure 44: Unmet needs for DS
  • Figure 45: Market Size of Down syndrome in 7MM in USD Million (2017-2030)
  • Figure 46: Market Size of Down syndrome in the US, USD Millions (2017-2030)
  • Figure 47: Therapy Based Market Size of Down syndrome in the US in USD Million (2017-2030)
  • Figure 48: Market Size of Down syndrome in Germany, USD Millions (2017-2030)
  • Figure 49: Therapy Based Market Size of Down syndrome in Germany in USD Million (2017-2030)
  • Figure 50: Market Size of Down syndrome in France, USD Millions (2017-2030)
  • Figure 51: Therapy Based Market Size of Down syndrome in France in USD Million (2017-2030)
  • Figure 52: Market Size of Down syndrome in Italy, USD Millions (2017-2030)
  • Figure 53: Therapy Based Market Size of Down syndrome in Italy in USD Million (2017-2030)
  • Figure 54: Market Size of Down syndrome in Spain, USD Millions (2017-2030)
  • Figure 55: Therapy Based Market Size of Down syndrome in Spain in USD Million (2017-2030)
  • Figure 56: Market Size of Down syndrome in the UK, USD Millions (2017-2030)
  • Figure 57: Therapy Based Market Size of Down syndrome in the UK in USD Million (2017-2030)
  • Figure 58: Market Size of Down syndrome in Japan, USD Millions (2017-2030)
  • Figure 59: Therapy Based Market Size of Down syndrome in Japan in USD Million (2017-2030)
  • Figure 60: Market Drivers
  • Figure 61: Market Barriers